SBIR-STTR Award

Novel microwave hyperthermal system for prostate cancer
Award last edited on: 6/2/2009

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$564,507
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Arkady S Dvinsky

Company Information

Daat Research Corporation

PO Box 5484
Hanover, NH 03755
   (603) 643-2999
   info@daat.com
   www.daat.com
Location: Single
Congr. District: 02
County: Grafton

Phase I

Contract Number: 1R43CA057037-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1992
Phase I Amount
$49,997
As prostate cancer has recently become the most widely diagnosed form of cancer in United States' males, clinicians are expected to seek more effective treatment modalities. One of these may be hyperthermia as an adjunct to radiation and chemotherapy. The main limitation to this mode of therapy has been the lack of effective heating equipment for the prostatic region.A novel two-applicator microwave heating system has been proposed for heating the prostate. Two applicators inserted transurethrally and transrectally would provide a multiple antenna array around the prostate tumor.Choked microwave antennas in the applicators would limit heating to the prostatic region. Air cooling of the applicator's surfaces would prevent damage to the rectal mucosa and the urethelium. Phase modulation among the antennas would allow uniform heating of the entire prostate. In Phase I, the applicants have proposed to design, construct, and test such an antenna array system. Experiments to test system efficacy would be performed in tissue equivalent phantom to determine power deposition profiles and steady-state temperature profiles. Modifications to improve system performance would be made as necessary. The goal of Phase I is to develop a system in preclinical animal experiments and clinical trials in Phase II

Phase II

Contract Number: 2R44CA057037-02A1
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1995
(last award dollars: 1996)
Phase II Amount
$514,510

Prostate cancer has become the most commonly diagnosed form of cancer, and is the second leading cause of cancer death among males in the United States. There are about 125,000 new cases of prostate cancer reported each year and about 30,000 deaths from this disease. Boosting the efficacy of radiation therapy with hyperthermia (which is heating to above 43 deg.C) may improve the prognosis of prostate cancer patients, since there is a positive correlation between local control and disease-specific survival. Innovative microwave hyperthermia applicators for insertion into the urethra and rectum would be characterized by their three- dimensional pattern of power deposition for typical separations and angles encountered in the clinic. The ability of the applicators to focus energy deposition through use of driving-phase differences would be evaluated. The applicators would be used to heat perfused canine prostates, and the three-dimensional temperature pattern in this site would be quantified. The ability of the applicators' surface-cooling systems to protect the urethra and rectal mucosa would be evaluated. The histopathology of prostatic and periprostatic tissue would be correlated with local temperature. Disposable versions of the applicators suitable for commercial production would be developed